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RESUMO: As funções das oncoproteínas E6 e E7 do 
Papilomavírus Humano tipo 16 (HPV-16) na progressão de 
células epiteliais imortalizadas para tumores invasivos não são 
totalmente compreendidas. Aqui, estabelecemos uma nova ligação 
entre E6 e E7 de duas variantes moleculares de HPV-16 (AA e 
E-350G) e c-MYC, em relação à cooperação na promoção da 
transformação maligna de queratinócitos humano primários de 
prepúcio de recém-nascido (PHK). Nosso objetivo foi estudar 
os efeitos sinérgicos de E6/E7 e c-MYC na proliferação e no 
potencial de transformação in vitro de PHKs. Avaliou-se a 
proliferação celular através da expressão proteica do Antígeno 
Nuclear de Células Proliferantes (PCNA). Também avaliamos 
a capacidade de transformação, in vitro, dos PHKs através de 
dois ensaios complementares. Observamos que E-350G-c-MYC 
PHKs exibiram um aumento discreto na expressão de PCNA e 
formaram significativamente mais colônias tanto nos ensaios de 
soft-ágar quanto nos ensaios em placas de cultura de baixa adesão. 
No geral, concluímos que a variante E-350G co-transfectada com 
c-MYC pode promover a transformação celular maligna com 
eficiência maior do que a variante AA-c-MYC. As propriedades 
oncogênicas exibidas pela variante E-350G permitem entender em 
maior detalhe os mecanismos que podem levar à neoplasia cervical 
humana, dada a maior frequência de sua ocorrência na progressão 
de lesões precursoras de alto grau para carcinomas invasivos.
Descritores: Papillomavirus humano 16; Transformação celular 
viral; Genes myc; Queratinócitos; Proteínas oncogênicas.
ABSTRACT: The roles of E6 and E7 oncoproteins of Human 
Papillomavirus type 16 (HPV-16) in the progression of 
immortalized epithelial cells to invasive tumors are not fully 
understood. Here, we establish a novel link between E6 and 
E7 of two molecular variants of HPV-16 (AA and E-350G), 
and c-MYC, regarding the cooperation in promoting malignant 
transformation of primary human foreskin keratinocytes (PHK). 
We aimed to study the synergistic effects of E6/E7 and c-MYC 
upon proliferation, and the in vitro transformation potential of 
PHK. We evaluated cellular proliferation through the expression 
of the Proliferating Cell Nuclear Antigen (PCNA) protein and 
colony formation abilities using soft agar and low attachment 
plates. We observed that E-350G-c-MYC PHKs exhibited discrete 
higher PCNA levels and formed significantly more colonies in 
both soft-agar and when growth in low-adhesion culture plates. 
Overall, we concluded that the E-350G variant co-transfected 
with c-MYC might promote malignant cellular transformation 
with a better efficiency than the AA-c-MYC counterpart. The 
enhanced oncogenic properties exhibited by the E-350G-c-MYC 
variant offer insights into mechanisms that may operate in human 
cervical neoplasia, given the higher frequency of its occurrence 
in the progression of high-grade precursor lesions to invasive 
carcinomas.
Keywords: Human papillomavirus 16; Cellular transformation, 
viral;  Genes, myc; Keratinocytes; Oncogene proteins.
53
Hochmann J, et al. Cooperative role of c-MYC and E6/E7 from two molecular variants of human papillomavirus 
.
INTRODUCTION
High-risk Human Papillomavirus (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 y 68) are 
the main etiological agent of cervical cancer. HPV-16 
is the most prevalent type and is responsible for about 
500,000 new cancer cases and over 250,000 cancer deaths 
worldwide every year. HPV variants arise in consequence 
of cumulative nucleotide mutations in key positions of 
the viral genome and differ in nucleotide sequence by no 
more than 2% in coding regions and until 5% in the non-
coding region1. Data obtained from 301 HPV-16 positive 
cervical samples from 25 different geographical regions 
in the world revealed that HPV-16 has evolved along five 
major branches, two being present mainly in Africa, one 
Asian-American, one Asian and one in Europe2,3. The 
E6/E7 oncogenes of high-risk HPVs are both necessary 
and sufficient to immortalize Primary Human Foreskin 
Keratinocytes (PHKs), and their expression is required 
for the continued proliferation of HPV-positive cervical 
cancer cells4,5. However, these immortalized cells are not 
tumorigenic in mice, which means that addition. Cellular 
events are required for the complete transformation of 
human epithelial cells. Several observations suggest that 
cooperative signaling of host cellular factors, along with E6 
and E7, are essential in promoting entire tumor progression 
in vivo6. 
One of the most studied human oncogenes is RAS 
which expression leads the immortalized human epithelial 
cells to a fully transformed phenotype with all the hallmarks 
of cancerous cells7,8. It has also been shown that c-MYC can 
replace Notch1 in cooperating with HPV-16 E6 and E7 in 
the transformation of human epithelial cells since c-MYC 
is a direct t.arget of CBF1-dependent signaling triggered 
by activated Notch19. 
Although exacerbated levels of c-MYC are observed 
in many cases of cervical cancer, the function of c-MYC in 
the process of HPV-mediated transformation is unclear. E6 
is believed to directly transactivate the c-MYC promoter 
in H358 (bronchio.alveolar carcinoma/non-small cell lung 
cancer) and C33a (cervical cancer HPV negative) cells10. 
On contrast, other reports suggest that E6 controls the 
degradation of c-MYC in a neuroblastoma cell line that 
expresses high levels of the human N-MYC protein11. In 
addition, it was observed that c-MYC associates with the 
HPV-16 E6 protein in vivo to transactivate the hTERT 
promoter in PHKs12. As seen, the mechanisms through E6 
leads to transformation can be cell-type specific.
c-MYC belongs to the myc family of genes (MYC, 
MYCN, MYCL), is located on chromosome 8q24.1, has 
three exons and encodes a nuclear protein of 62 kDa that 
holds transcription factor activity and responds to different 
cell signaling pathways which are responsive to cellular 
growth factors13. The c-MYC gene is frequently activated 
in human cancers through several mechanisms, such as 
mutations14,15,16, or even, as a result of the inactivation of 
key controllers of the cell cycle, such as p5313. 
In this study, we analyzed the putative function of 
c-MYC in HPV-mediated transformation of PHKs as an 
important partner of E6 and E7 proteins of two molecular 
variants of HPV-16: Asian-American (AA) and European 
with the 350G substitution (E-350G). Here we demonstrated 
that cells co-transduced with E-350G and c-MYC presented 
an enhanced in vitro transformation potential in comparison 
to AA and c-MYC co-expressing cells. 
MATERIAL AND METHODS
Transduction of c-MYC in primary human keratinocytes 
(PHK), co-transduced or not with E6/E7 of two HPV-16 
molecular variants (AA and E-350G) 
Pools of primary newborn foreskin human 
keratinocytes (PHK) were purchased from Clonetics, 
NJ, USA (cat n. 00192906, lot n. 0000252415, certificate 
of analysis provided by the supplier), and maintained in 
keratinocyte serum-free medium (KSFM) supplemented 
with 5ng/mL epidermal growth factor (EGF) and 50µg/
mL bovine p.ituitary extract (BPE) (Invitrogen, CA, 
USA). PHKs immortalized by E6 and E7 from different 
molecular variants of HPV-16 were obtained as previously 
described17,18. HPV-immortalized cells used in this study 
were tested internally for HPV DNA status, viral RNA 
expression patterns, and E6/E7 protein expression levels. 
HPV transduced cells were continuously sub-cultured 1:6 
when 80–90% confluence was reached and considered 
immortalized after 30 passages19. PHKs immortalized 
with two distinct HPV-16 variants were used throughout 
this study: E-350G (E6:L83V), and AA (E6:Q14H/H78Y/
L83AA). We infected primary and high passage (›p100) E6/
E7 PHKs w.ith the lentiviral pCDH-puro-c-MYC plasmid 
(Addgene # 46970). Briefly, 10µg of this plasmid was 
co-transfected with three plasmids encoding the lentiviral 
proteins Gag, Pol, Env in HEK293T cells using a calcium 
phosphate protocol. Infectious particles were used to infect 
HPV-immortalized and normal PHKs using a MOI of 5 in 
presence of 8 µg/mL of polybrene. 
Proliferation assay
Cell lines (PHK, AA, AA-c-MYC, E-350G, and 
E-350G-c-MYC) were harvested by trypsin digestion and 
seeded into 6-well cell culture plates (1×104 cells/well) 
at day 0. Cells were dissociated from wells with 0.25% 
trypsin and counted every other day manually using a 
hemocytometer under a microscope. Cell growth curves 
were obtained from live cell numbers during six days.
Clonogenic assay 
Primary cells, PHKs transducing c-MYC, or PHKs 
co-transducing E6/E7 of two variants of HPV-16 and 
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c-MYC (E-350G-c-MYC and AA-c-MYC) were seeded 
at low de.nsity (300 cells) in six wells plates. After two 
weeks with medium changed every other day, cells were 
stained with 0.01% crystal violet, and colonies were 
counted macroscopically. Experiments were performed at 
least in triplicates three times independently. Colonies were 
counted by using the VisionWorks™LS Image Acquisition 
and Analysis software (UVP, Jena, Germany).
Soft agar assay 
One of the hallmarks of transformed cells consists 
on the ability to grow independent of substrate adhesion. 
The anchorage-independent condition can be recreated 
in vitro using a semi-solid medium. For this assay, 7,000 
cells were mixed with 0.3% low melting point (LMP) 
agarose in KSFM medium and seeded in 24 wells plates 
on top of a 1% LMP agarose bed. After 20 days, colonies 
were stained using 1mg/mL MTT (Sigma, MI, USA), and 
observed macroscopically to visualize the number and size 
of the colonies formed. Experiments were conducted three 
times in six replicates.
Immunoblot 
Cells pellets were washed with ice-cold phosphate-
buffered saline (PBS), centrifuged, and protein lysates 
extracted by incubation on ice for 30 min with RIPA 
buffer (20 mM Tris–HCl, pH=7.5, 150 mM NaCl, 0.5% 
sodium deoxycholate, 1% NP-40, 0.1% SDS) containing 
complete protease and phosphatase inhibitor cocktails 
(Roche, Basel, Switzerland). Eighty micrograms of protein 
extracts were loaded onto 10–15% SDS-polyacrylamide 
gels, electrophoresed, and transferred to PVDF membranes 
(GE Healthcare, Buckinghamshire, UK). The primary 
antibodies were used at the following dilutions: anti-
cMYC (ab69987, 1:250), anti-PCNA (ab29, 1:1000), 
and anti-tubulin (1:5,000, OT-9026, Sigma, MI, USA). 
Anti-rabbit or anti-mouse HRP-conjugated secondary 
antibodies (GE Healthcare Buckinghamshire, UK) were 
used at a dilution of 1:5000. Proteins were visualized 
using the ECL Plus Western Blotting detection system (GE 
Healthcare, Buckinghamshire, UK) in a ImageQuant LAS 
4000 equipment (GE Healthcare, Buckinghamshire, UK). 
Protein levels were quantified using the ImageQuant TL 
software (GE Healthcare, Buckinghamshire, UK).
Low attachment assay
We seeded 50,000 cells on low attachment six well 
plates with 5mL of KSFM. Every three days 500µL of 
KSFM were added to each well. After thirteen days, colo.
nies were photographed using the EVOS FL Auto Imaging 
System AMAFD 1000 (Life Technologies, MA, USA), and 
25 photos were obtained for each well. Experiments were 
conducted three times in triplicates.
Statistical analysis
Mean values and standard deviation (SD) are shown. 
Whenever appropriate, data was analyzed by unpaired two-
tailed Student´s t-test using GraphPad Prism Version 7, and 
ANOVA for repeated measures to compare proliferation 
rates using SPSS v.25 for Windows. Significance level was 
5% for all hypothesis.
RESULTS
Characterization of PHKs co-transduced with E6/E7 
of two HPV-16 variants and c-MYC
We initially transduced c-MYC in HPV-16 
immortalized keratinocytes. As expected, PHKs co-infected 
with AA-c-MYC or E-350G-c-MYC exhibited higher 
levels of c-MYC expression relative to PHKs transduced 
only with E6/E7 of HPV-16 or normal PHKs (Figure 
1a,b). However, the increment in cMYC expression was 
statistically significant solely for PHKs transduced with 
E-350G-c-MYC. 
Figure 1. Characterization of PHKs immortalized by E6/E7 of two HPV-16 variants co-transduced with c-MYC. (A) Total protein extracts 
were submitted to SDS-PAGE followed by immunobloting using antibody against c-MYC. One representative experiment of two independent 
assays is shown. (B) Densitometric analysis of c-MYC protein expression of parental cells and HPV-16 immortalized PHKs co-transduced not 
with c-MYC. Values were normalized to tubulin expression levels, and averages ± SDs from two independent experiments are shown
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E6/E7 HPV-16 immortalized PHKs transduced with 
c-MYC do not significantly differ in their proliferative 
potential
We inquired whether c-MYC increases the 
proliferation rate of HPV-16 immortalized PHKs. Our 
results showed that PHKs co-transduced with the E-350G 
variant and c-MYC presented a discrete but not statistically 
significant increment in PCNA expression levels relative to 
that of AA-c-MYC PHKs (Figure 2a,b).Furthermore, we 
evaluated the growth rate of these cells over a period of 
6 days in culture and observed no significant differences 
among cells immortalized by the different HPV-16 variants 
and those co-transduced with HPV-16 and c-MYC. Taken 
together, our data shows that independently of the variant 
analyzed, HPV-16 immortalized PHKs transduced with 
c-MYC do not attain differences regarding proliferation.
Colony formation and transformation potentials of 
immortalized human keratinocytes co-transduced or 
not with c-MYC
The cooperative role of c-MYC and E6/E7 from 
two HPV-16 variants upon in vitro transformation was 
evaluated using three different approaches: We initially 
carried out clonogenic assays by plating cells in low density 
and allowing colonies to grow for two weeks. Our results 
showed that both variants co-transfected with c-MYC 
formed significantely more colonies when compared to 
PHKs. In addition, PHKs co-transduced with the E-350G 
variant and c-MYC formed even more colonies when 
compared to PHKs co-transduced with the AA variant and 
c-MYC (Figure 3a,b). However, no significant differences 
were found regarding the colony diameter (Figure 3c). 
Next, cells were plated in semi-solid medium and we 
observed that PHKs co-transduced with the E-350G variant 
and c-MYC were also able to produce a significantly 
higher number of colonies relative to the AA-c-MYC 
variant counterpart (Figure 4 a and b). Finally, our data 
was further corroborated using an assay that mimics 3D 
growth conditions, showing a more efficiency in the number 
of colonies formed by E-350G-c-MYC variant (Figure 4 c 
and D). In sum, our results point towards a higher in vitro 
transformation potential for the HPV-16 E-350G variant 
in cooperation with c-MYC.
Figure 2. Proliferation ability of PHKs immortalized by E6/E7 of two HPV-16 variants co-transduced with c-MYC. (a) Expression profile of the 
PCNA protein. Total protein extracts from parental and immortalized PHKs co-transduced or not with c-MYC, were submitted to SDS-PAGE 
followed by immunoblotting using an antibody against the proliferating cell nuclear antigen (PCNA). One representative experiment of two 
independent assays is shown. (b) Densitometric analysis of PCNA levels in parental cells and HPV-16 immortalized PHKs co-transduced or 
not with c-MYC. Values were normalized to tubulin expression levels, and averages ±SDs of two independent experiments are shown. (c) Cell 
growth curves over a six days period of normal, and HPV-16 immortalized PHKs transduced or not with c-MYC. Cell numbers were accessed 
manually with a hemocytometer under a microscope. One representative experiment of two independent assays is shown
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Figure 4. Transformation potential of HPV-16 immortalized and c-MYC co-transduced cells. a) Soft agar assay. After 15 days in 
culture colonies were stained with MTT and evaluated macroscopically. b) Colony number was accessed for each cell line by counting 
manually. Averages and ±SDs from three independent experiments are shown. c) Low attachment assay. After 15 days, 25 photographs 
were taken from each cell line using the EVOS equipment. d) Colony number was accessed for each cell line by counting manually. 
Averages and ±SDs from three independent experiments are shown
Figure 3. Colony formation potential of HPV-16 immortalized and c-MYC co-transduced cells when plated in low density. (a) For all 
cultures, 300 cells were seeded in triplicates and grown in six-well plates for 15 days. Colonies formed were visualized by staining with 
crystal violet and evaluated macroscopically. One representative experiment of three is shown. (b) and (c) Colony number and size were 
accessed using the the VisionWorks™LS Image Acquisition and Analysis software (UVP, Jena, Germany). Averages and ±SDs from 
three independent experiments are shown
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DISCUSSION
Expression of high-risk HPVs E6 and E7 
oncoproteins is necessary for the immortalization of 
primary keratinocytes, a critical step for oncogenic 
progression, however insufficient for the complete in vivo 
transformation of these cells. Thus, the contribution of a 
host factor would be necessary to achieve a transformed 
phenotype6. It has been previously reported that c-MYC 
can replace activated Notch 1 in synergizing with HPV-16 
E6 and E7 oncoproteins towards cell transformation, once 
c-MYC expression is regulated by Notch19. 
In the present study, we evaluated the cooperative 
role between E6/E7 of two different variants of HPV-
16 and c-MYC upon PHK proliferation and in vitro 
transformation using different approaches. Taken together, 
our data supports a higher transformation potential for the 
European molecular variant of HPV-16 with a nucleotide 
substitution in the E6 gene (E-350G) in collaboration 
with c-MYC in comparison to HPV-16 AA immortalized 
PHKs further transduced with this cellular gene (AA-
cMYC-PHK). Our results corroborate a previous study 
that showed that c-MYC can cooperate with HPV-16 
E6 and E7 oncogenes in cell transformation since the 
introduction of AcN1 or c-MYC in HaCaT(transformed 
keratinocyte of human skin) cells expressing E6 and E7 
resulted in a greater than 4-fold increase in the number 
of colonies formed on soft agar assays when compared 
to mock-transfected, or cells expressing solely HPV-16 
E6/E79. Furthermore, Chakrabarti et al.20 reported that 
the E-350G HPV-16 variant enhances MAPK signaling 
and cooperative transformation with deregulated Notch1, 
allowing the progression of immortalized human epithelial 
cells to a complete transformation as accessed using in 
vitro soft agar assay. 
The enhanced oncogenic potential exhibited by the 
E-350G variant offer insights into mechanisms that may 
operate in human cervical carcinogenesis. In European 
populations mostly all HPV-16 molecular variants detected 
belong to the European branch21,22. In Europe,  the HPV-
16 E-350G variant has been shown to associated with an 
increased risk of viral infection persistence and progression 
to cervical intraepithelial neoplasia 2 and 3 (CIN2 and 3) 
and invasive cervical cancer in some populations21,22,23. 
The fact that our data points towards a higher oncogenic 
l attributed to this variant in cooperation with c-MYC, 
may explain, at least in part, why women infected with 
the E-350G variant are more prone to develop cervical 
neoplasias. Nevertheless, it should be highlighted that not 
all studies conducted in different European populations 
showed similar results24,25,26,27,28,29. 
In conclusion, our results indicate that HPV-16 
E6/E7 cooperates with c-MYC in promoting in vitro 
transformation of PHKs. More specifically, we further 
demonstrated that E-350G-c-MYC PHKs showed the 
highest oncogenic potential. Nevertheless, further studies 
are needed to elucidate the molecular mechanisms by which 
HPV-16 variants differ in their oncogenic potential. 
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